ArticleInternational journal of cancer2026
HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Novel Exploratory Transcriptomic Candidates as Biomarkers and Cancer Hallmark Fingerprints for Ovarian Endometroid and Clear Cell Carcinomas in Women.Antioxidants (Basel, Switzerland) · 2026Article
- Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigms.Oncology reviews · 2026Review
- A coupled iron-hypoxia selection model for the evolution of endometriosis-associated ovarian clear cell carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Ovarian clear cell carcinoma (CCC) is an aggressive subtype of ovarian cancer that is resistant to conventional chemotherapy, resulting in poor prognosis. CCC develops from endometriosis, which exposes tumor cells to a hypoxic microenvironment, thereby highlighting the critical role of hypoxia in ovarian CCC progression. Thus, identifying novel therapeutic targets, particularly those associated with hypoxia, is important. Hypoxia-inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian CCC remains unclear. This study assessed the prognostic and functional significance of HIF2A in ovarian CCC and investigated its potential as a therapeutic target. Inhibiting HIF2A significantly suppressed ovarian CCC tumor growth through a genetic knockdown cell line as well as pharmacological inhibition using a novel HIF2A inhibitor, NKT2152. In vitro experiments showed that HIF2A suppression enhanced mitochondrial respiration and increased mitochondrial reactive oxygen species production alongside the downregulation of HIF2A target genes. Moreover, treatment with NKT2152 significantly reduced tumor growth in both cell line-derived and patient-derived xenograft models. In conclusion, our findings provide novel insights into the prognostic and functional role of HIF2A in ovarian CCC and underscore its potential as a promising therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.